{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:12:46Z","timestamp":1787497966647,"version":"build-2736575974"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"\n Importance<\/jats:title>\n Individuals with allergic contact dermatitis to one topical corticosteroid may also react to other corticosteroids. Corticosteroid classification models have been proposed to predict such copositivity, recommend representative screening corticosteroids, and guide allergen avoidance.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To use patient data to determine copositivity patterns between corticosteroids and evaluate against previous corticosteroid classification models.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This qualitative study included a retrospective analysis of the Mayo Clinic Contact Dermatitis Group corticosteroid patch test data from 2010 to 2019. Among patients undergoing patch testing with the Mayo Clinic\u2019s standard or steroid series who consented to research participation, 5637 patients were included in the analysis. Copositivity rates were determined between corticosteroids and analyzed by hierarchical clustering for comparison to previous classification models.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The frequency of patch test positivity to each of the analyzed corticosteroids was noted and compared with previously published patch test positivity rates. Copositivity rates between each pair of corticosteroids were determined, and overall copositivity patterns were analyzed and evaluated against known steroid classes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 49\u202f472 individual patches were applied to 5637 patients, testing 18 corticosteroids. Patch test positivity rates ranged between 0.3% and 4.7%. The fluocinonide positivity rate corresponded to the highest copositivity rate with other corticosteroids (mean [SD], 50.7% [26.1%]). Tixocortol-21-pivalate, 0.1%, and tixocortol-21-pivalate, 1%, positivity rates corresponded to the lowest copositivity rates (mean [SD], 4.1% [1.7%] and 3.6% [1.4%], respectively). Hierarchical clustering elucidated patterns that did not support previous corticosteroid classification models.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this qualitative study, copositivity rates were variable between corticosteroids, and overall patch test positivity for allergy to topical corticosteroids was rare. Previously published corticosteroid classifications are not supported by real patient-derived data and may not be accurate in predicting corticosteroid copositivity.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.3774","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T11:36:34Z","timestamp":1664364994000},"page":"1279","source":"Crossref","is-referenced-by-count":18,"title":["Reevaluating Corticosteroid Classification Models in Patient Patch Testing"],"prefix":"10.1001","volume":"158","author":[{"given":"Joyce Y.","family":"Chen","sequence":"first","affiliation":[{"name":"Mayo Clinic Alix School of Medicine, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Yiannias","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly J.","family":"Youssef","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Drage","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D. P.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yul W.","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"doi220049r1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1034\/j.1398-9995.2000.00121.x","article-title":"Contact allergy to corticosteroids.","volume":"55","author":"Matura","year":"2000","journal-title":"Allergy"},{"issue":"1","key":"doi220049r2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/DER.0000000000000251","article-title":"Patch test reactions to corticosteroids: retrospective analysis from the North American Contact Dermatitis Group 2007-2014.","volume":"28","author":"Pratt","year":"2017","journal-title":"Dermatitis"},{"issue":"1","key":"doi220049r3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/bjd.1989.121.issue-1","article-title":"Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids.","volume":"121","author":"Coopman","year":"1989","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi220049r4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/archderm.1995.01690130033006","article-title":"Studies in patients with corticosteroid contact allergy: understanding cross-reactivity among different steroids.","volume":"131","author":"Lepoittevin","year":"1995","journal-title":"Arch Dermatol"},{"issue":"10","key":"doi220049r5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/all.2011.66.issue-10","article-title":"Corticosteroid cross-reactivity: clinical and molecular modelling tools.","volume":"66","author":"Baeck","year":"2011","journal-title":"Allergy"},{"issue":"6","key":"doi220049r6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jaad.2006.11.012","article-title":"Results of patch testing to a corticosteroid series: a retrospective review of 1188 patients during 6 years at Mayo Clinic.","volume":"56","author":"Davis","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi220049r7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/DER.0000000000000798","article-title":"Contact allergy cross-reactions and thresholds: a review.","volume":"33","author":"Scheman","year":"2022","journal-title":"Dermatitis"},{"issue":"4","key":"doi220049r8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jaad.2005.12.028","article-title":"Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity.","volume":"54","author":"Jacob","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi220049r9","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/DER.0000000000000595","article-title":"Defining topical corticosteroids by allergenicity and cross-reactivity for the contact allergen management program.","volume":"31","author":"Gupta","year":"2020","journal-title":"Dermatitis"},{"issue":"5","key":"doi220049r10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/DER.0b013e31829cb0d1","article-title":"The relevance of 7-day patch test reading.","volume":"24","author":"Higgins","year":"2013","journal-title":"Dermatitis"},{"issue":"4","key":"doi220049r11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/DER.0000000000000297","article-title":"Delayed patch-test reading after 5 days: an update from the Mayo Clinic Contact Dermatitis Group.","volume":"28","author":"Chaudhry","year":"2017","journal-title":"Dermatitis"},{"issue":"1","key":"doi220049r12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cod.2007.57.issue-1","article-title":"Tixocortol pivalate: what is the right concentration?","volume":"57","author":"Kalavala","year":"2007","journal-title":"Contact Dermatitis"},{"issue":"5 pt 1","key":"doi220049r13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0190-9622(98)70197-5","article-title":"Contact hypersensitivity to tixocortol pivalate.","volume":"38","author":"Lutz","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi220049r14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1600-0536.1991.tb01809.x","article-title":"Hydrocortisone sensitivity: a prospective study of the value of tixocortol pivalate and hydrocortisone acetate as patch test markers.","volume":"25","author":"Wilkinson","year":"1991","journal-title":"Contact Dermatitis"},{"issue":"4","key":"doi220049r15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/archderm.1979.04010040018005","article-title":"Skin levels and vasoconstrictor assay of topically applied hydrocortisone.","volume":"115","author":"Wallace","year":"1979","journal-title":"Arch Dermatol"},{"issue":"3","key":"doi220049r17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/cod.2009.61.issue-3","article-title":"Delayed hypersensitivity to corticosteroids in a series of 315 patients: clinical data and patch test results.","volume":"61","author":"Baeck","year":"2009","journal-title":"Contact Dermatitis"},{"issue":"3","key":"doi220049r18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1600-0536.1995.tb00535.x","article-title":"Screening for corticosteroid contact hypersensitivity.","volume":"33","author":"Boffa","year":"1995","journal-title":"Contact Dermatitis"},{"key":"doi220049r16","unstructured":"Topical dermatologic corticosteroids: in vivo bioequivalence. US Food and Drug Administration. Accessed August 17, 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/topical-dermatologic-corticosteroids-in-vivo-bioequivalence"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2796420\/jamadermatology_chen_2022_oi_220049_1668194621.17535.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T11:01:46Z","timestamp":1668596506000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2796420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.3774","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}